FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313363437> ?p ?o ?g. }

• W4313363437 endingPage "380" @default.
• W4313363437 startingPage "365" @default.
• W4313363437 abstract "Timely, effective, and safe antiviral therapy in COVID-19 patients reduces complications, disability and mortality rates. The greatest concern with remdesivir is the risk of drug-induced liver injury, including in patients whose liver function is compromised by COVID-19. The aim of the study was to investigate the efficacy and safety of remdesivir in patients with confirmed SARS-CoV-2 infection who had been admitted to an infectious diseases hospital in the Volgograd region in March 2022. Materials and methods: the authors carried out an open, non-randomised, single-arm study using medical records of 234 patients who had been diagnosed with “U07.1 COVID-19, virus identified” and prescribed remdesivir upon admission. The effectiveness of therapy was evaluated using two criteria: the need for oxygen supplementation or ventilatory support, or mortality. The authors conducted the evaluation on days 7, 14, and 28 using the six-point ordinal severity scale by Y. Wang et al. The safety of therapy was assessed on the basis of complaints and changes in laboratory findings. Results: for the patients prescribed remdesivir at admission, the 7-day mortality rate was 3.0%, the 14-day mortality rate was 5.6%, and the 28-day mortality rate was 7.3%. With the exception of a patient with myocardial infarction, all the patients who had been hospitalised with mild COVID-19 and prescribed remdesivir did not require oxygen therapy and/or transfer to intensive care and were discharged following recovery. The patients with moderate to severe COVID-19 had the 14-day mortality rate of 6.4% and the 28-day mortality rate of 8.6%. 17 patients (7.2%) discontinued remdesivir prematurely for various reasons, including adverse drug reactions. Remdesivir therapy of 5-10 days was associated with an increase in ALT activity by 2.7 ± 0.8 times in 15.9% of patients with mild COVID-19, by 3.8 ± 1.8 times in 20.4% of patients with moderately severe COVID-19, and by 4.8 ± 2.7 times in 24% (12/50) of patients with severe COVID-19. In two patients (0.9%), the increase exceeded 10-fold the upper limit of normal. Conclusions : the obtained results support recommending remdesivir to patients with mild, moderate and severe COVID-19, including those with moderately elevated baseline activity of hepatic transaminases." @default.
• W4313363437 created "2023-01-06" @default.
• W4313363437 creator A5007858214 @default.
• W4313363437 creator A5030510910 @default.
• W4313363437 creator A5053650626 @default.
• W4313363437 creator A5070957793 @default.
• W4313363437 date "2022-12-29" @default.
• W4313363437 modified "2023-09-30" @default.
• W4313363437 title "Experience of Using Remdesivir in Patients with Novel Coronavirus Infection" @default.
• W4313363437 cites W2924328881 @default.
• W4313363437 cites W2991491848 @default.
• W4313363437 cites W3013384091 @default.
• W4313363437 cites W3015221761 @default.
• W4313363437 cites W3015256585 @default.
• W4313363437 cites W3018023298 @default.
• W4313363437 cites W3027630905 @default.
• W4313363437 cites W3032677067 @default.
• W4313363437 cites W3042516758 @default.
• W4313363437 cites W3080718665 @default.
• W4313363437 cites W3110466220 @default.
• W4313363437 cites W3168404616 @default.
• W4313363437 cites W3201561713 @default.
• W4313363437 cites W3204108803 @default.
• W4313363437 cites W4200206478 @default.
• W4313363437 cites W4207079981 @default.
• W4313363437 cites W4225553089 @default.
• W4313363437 cites W4226023710 @default.
• W4313363437 cites W4229363631 @default.
• W4313363437 cites W4280650748 @default.
• W4313363437 cites W4288042977 @default.
• W4313363437 doi "https://doi.org/10.30895/2312-7821-2022-10-4-365-380" @default.
• W4313363437 hasPublicationYear "2022" @default.
• W4313363437 type Work @default.
• W4313363437 citedByCount "0" @default.
• W4313363437 crossrefType "journal-article" @default.
• W4313363437 hasAuthorship W4313363437A5007858214 @default.
• W4313363437 hasAuthorship W4313363437A5030510910 @default.
• W4313363437 hasAuthorship W4313363437A5053650626 @default.
• W4313363437 hasAuthorship W4313363437A5070957793 @default.
• W4313363437 hasBestOaLocation W43133634371 @default.
• W4313363437 hasConcept C126322002 @default.
• W4313363437 hasConcept C179755657 @default.
• W4313363437 hasConcept C194828623 @default.
• W4313363437 hasConcept C2779123688 @default.
• W4313363437 hasConcept C2779134260 @default.
• W4313363437 hasConcept C2780630273 @default.
• W4313363437 hasConcept C3008058167 @default.
• W4313363437 hasConcept C524204448 @default.
• W4313363437 hasConcept C71924100 @default.
• W4313363437 hasConceptScore W4313363437C126322002 @default.
• W4313363437 hasConceptScore W4313363437C179755657 @default.
• W4313363437 hasConceptScore W4313363437C194828623 @default.
• W4313363437 hasConceptScore W4313363437C2779123688 @default.
• W4313363437 hasConceptScore W4313363437C2779134260 @default.
• W4313363437 hasConceptScore W4313363437C2780630273 @default.
• W4313363437 hasConceptScore W4313363437C3008058167 @default.
• W4313363437 hasConceptScore W4313363437C524204448 @default.
• W4313363437 hasConceptScore W4313363437C71924100 @default.
• W4313363437 hasIssue "4" @default.
• W4313363437 hasLocation W43133634371 @default.
• W4313363437 hasOpenAccess W4313363437 @default.
• W4313363437 hasPrimaryLocation W43133634371 @default.
• W4313363437 hasRelatedWork W3034905468 @default.
• W4313363437 hasRelatedWork W3046017510 @default.
• W4313363437 hasRelatedWork W3046103043 @default.
• W4313363437 hasRelatedWork W3081722904 @default.
• W4313363437 hasRelatedWork W3094131409 @default.
• W4313363437 hasRelatedWork W3119258671 @default.
• W4313363437 hasRelatedWork W3198405553 @default.
• W4313363437 hasRelatedWork W4200573858 @default.
• W4313363437 hasRelatedWork W4249342726 @default.
• W4313363437 hasRelatedWork W3121947905 @default.
• W4313363437 hasVolume "10" @default.
• W4313363437 isParatext "false" @default.
• W4313363437 isRetracted "false" @default.
• W4313363437 workType "article" @default.